Tarsus Acquisition Target Alkeus Announces JAMA Ophthalmology Publication Of TEASE-1 Data Showing Gildeuretinol Cut Retinal Lesion Growth Rate 21.6% vs. Untreated In 50-Patient Stargardt Disease Trial

뉴스 본문을 불러오고 있어요.

Tarsus Acquisition Target Alkeus Announces JAMA Ophthalmology Publication Of TEASE-1 Data Showing Gildeuretinol Cut Retinal Lesion Growth Rate 21.6% vs. Untreated In 50-Patient Stargardt Disease Trial | 웨이프 WAPE

Tarsus Acquisition Target Alkeus Announces JAMA Ophthalmology Publication Of TEASE-1 Data Showing Gildeuretinol Cut Retinal Lesion Growth Rate 21.6% vs. Untreated In 50-Patient Stargardt Disease Trial

기사 요약

관련 종목

댓글 —